At 17.7% CAGR, the Middle East & Africa Organoids Market is projected to be worth US$ 245.34 million by 2030, says Business Market Insights

According to Business Market Insights research, the Middle East & Africa Organoids market was valued at US$ 66.44 million in 2022 and is expected to reach US$ 245.34 million by 2030, registering a CAGR of 17.7% from 2022 to 2030. Increasing demand for tumor modeling and biobanking and growing adoption of personalized drugs are the critical factors attributed to the Middle East & Africa Organoids market expansion.        

Organoids are microscopic and self-organizing 3D structures grown from stem cells in vitro. They review various structural and functional characteristics of their in vivo counterpart organs. This multipurpose technology has led to several novel human cancer models. It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer by introducing any combination of cancer gene alterations to normal organoids. Tumor organoids, when combined with immune cells and fibroblasts, become a model for the cancer microenvironment enabling immune-oncology applications. Also, recent studies have proved that organoids have a place in personalized medicine approaches.

The constant progress in organoid technology has paved the way for tumors and patient-centric 3D cultures of cells isolated from tumor biopsies. Over the past few decades, organoids have been generated from diverse human cancers associated with breast, colon, pancreas, prostate, bladder, and liver. Studies involving these models help in providing key facts about these malignancies. Due to constant advancements in the current scenario, tumoroid lines are increasingly being passed in vitro, opening new paths for a range of downstream applications. Moreover, 3D-based cultures offer added advantages over conventional 2D cancer-derived cell lines. Further, recent research and development activities have specified that tumoroid culturing is highly effective in allowing the collection of various cancer subtypes from a large pool of patients. As organoids can be easily derived and expanded from single cancer cells, the adoption of organoids to mimic intratumor diversification in culture is increasing, which, in turn, is propelling the Middle East & Africa organoids market.

Companies have been developing innovative biobanks for storing several biological samples, including tumors. For instance, OrganoidBase (developed by Crown Bioscience) consists of 342 tumor organoid models derived from patient-derived xenograft (PDX) models [i.e., PDX-derived organoids (PDXOs)]. PDXOs offer detailed information on histopathology, IC50, genomic, and transcriptomic analysis data associated with drug response; it also has an additional 217 models from primary patient samples. These PDXO models have varied indications, with multiple models derived from over 20 organ and tissue types. Crown Biosciences commercializes organoids in a 3D in vitro model derived using IP-protected Hubrecht Organoid Technology (HUB) protocols. Thus, such innovations are driving the market growth.

On the contrary, issues related to incorporation of organoids into existing workflows hampers the Middle East & Africa organoids market.  

Based on organ type, the Middle East & Africa organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held 23.1% share of Middle East & Africa organoids market in 2022, amassing US$ 15.33 million. It is projected to garner US$ 55.57 million by 2030 to expand at 17.5% CAGR during 2022–2030.   

Based on application, the Middle East & Africa organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held 29.7% share of Middle East & Africa organoids market in 2022, amassing US$ 19.71 million. It is projected to garner US$ 76.19 million by 2030 to expand at 18.4% CAGR during 2022–2030.

Based on source, the Middle East & Africa organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held 72.0% share of Middle East & Africa organoids market in 2022, amassing US$ 47.84 million. It is projected to garner US$ 182.28 million by 2030 to expand at 18.2% CAGR during 2022–2030.

Based on type, the Middle East & Africa organoids market is segmented into instruments, consumables, and services. The consumables segment held 57.6% share of Middle East & Africa organoids market in 2022, amassing US$ 38.26 million. It is projected to garner US$ 148.27 million by 2030 to expand at 18.5% CAGR during 2022–2030.  

Based on country, the Middle East & Africa organoids market has been categorized into the South Africa, Saudi Arabia, UAE, and the Rest of Middle East & Africa. Our regional analysis states that the Rest of Middle East & Africa captured 36.7% share of Middle East & Africa organoids market in 2022. It was assessed at US$ 24.40 million in 2022 and is likely to hit US$ 83.32 million by 2030, exhibiting a CAGR of 16.6% during 2022–2030.

Key players operating in the Middle East & Africa organoids market are Cellesce, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, among others.   

• In Aug 2021, InSphero AG announced that it is making its proprietary, patented 96- and 384-microwell plates available to researchers, enabling them to access the same plate technology used in the company’s flagship, assay-ready 3D InSight Human Liver Microtissues. The plates, engineered specifically for 3D cultures of spheroids and organoids, are available via InSphero’s online R&D Solutions Store.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com